Baidu
map

Cell:Hedgehog信号通路为何引发乳腺癌转移?

2014-11-20 佚名 生物谷

长链非编码RNA(lncRNAs)与乳腺癌有牵连,但其在癌症转移和肿瘤生长中的相关机制仍不甚明朗。 得克萨斯大学MD安德森癌症中心科学家报告说,刺猬(hedgehog)是一个独特的细胞信号转导通路(其已知能导致许多类型的癌症),亦可能是乳腺癌转移的背后机制。这种分子与BCAR4协同,给肿瘤生长转移提供方便。 我们研究BCAR4和Hedgehog信号通路所得的研究结果提供了证据证实,即lnc

长链非编码RNA(lncRNAs)与乳腺癌有牵连,但其在癌症转移和肿瘤生长中的相关机制仍不甚明朗。

得克萨斯大学MD安德森癌症中心科学家报告说,刺猬(hedgehog)是一个独特的细胞信号转导通路(其已知能导致许多类型的癌症),亦可能是乳腺癌转移的背后机制。这种分子与BCAR4协同,给肿瘤生长转移提供方便。

我们研究BCAR4和Hedgehog信号通路所得的研究结果提供了证据证实,即lncRNAs在侵袭性乳腺癌进展中起到重要调控角色。新获得的证据表明lncRNAs在癌症发展和进展中是一类新的调控因子。

当刺猬蛋白信号通路被趋化蛋白异常激活,它允许GLI2转录因子所控制的基因表达增加。转录因子是蛋白质,能激活其他基因。研究小组发现,BCAR4对于GLI2控制基因的激活是必需的。

BCAR4通过Hedgehog信号和GLI2所完成的分子间互作是乳腺癌中Hedgehog信号通路和BCAR4之间第一个被研究的联结点。这种新的研究发现导致Yang探索一个新兴的方法——锁核酸 (locked nucleic acids,LNA)治疗乳腺癌的潜力。他的相关研究成果发表在Cell杂志上。

lncRNAs治疗乳腺癌的潜能没有得到很好的证明。在我们的研究中,我们的目标是通过使用LNA为基础的治疗,以确定它们治疗乳腺癌的潜力。研究发现,在小鼠和人体组织细胞系,用LNA治疗乳腺肿瘤扩散,确实有一个好的治疗效果。

针对BCAR4的LNA治疗强烈抑制乳腺癌转移,我们证实靶向BCAR4和Hedgehog信号通路之间的联系可作为一种可行的方法来治疗侵袭性乳腺癌。

原始出处

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1868946, encodeId=f004186894614, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Feb 07 11:01:00 CST 2015, time=2015-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959192, encodeId=810119591920a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Oct 04 10:01:00 CST 2015, time=2015-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752430, encodeId=cefe1e5243001, content=<a href='/topic/show?id=0ded865662' target=_blank style='color:#2F92EE;'>#Hedgehog#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8656, encryptionId=0ded865662, topicName=Hedgehog)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=544436541072, createdName=yibei, createdTime=Sat Jun 27 14:01:00 CST 2015, time=2015-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539576, encodeId=c8ad15395e67c, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Sat Nov 22 06:01:00 CST 2014, time=2014-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590258, encodeId=6d2c159025835, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Sat Nov 22 06:01:00 CST 2014, time=2014-11-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1868946, encodeId=f004186894614, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Feb 07 11:01:00 CST 2015, time=2015-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959192, encodeId=810119591920a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Oct 04 10:01:00 CST 2015, time=2015-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752430, encodeId=cefe1e5243001, content=<a href='/topic/show?id=0ded865662' target=_blank style='color:#2F92EE;'>#Hedgehog#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8656, encryptionId=0ded865662, topicName=Hedgehog)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=544436541072, createdName=yibei, createdTime=Sat Jun 27 14:01:00 CST 2015, time=2015-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539576, encodeId=c8ad15395e67c, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Sat Nov 22 06:01:00 CST 2014, time=2014-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590258, encodeId=6d2c159025835, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Sat Nov 22 06:01:00 CST 2014, time=2014-11-22, status=1, ipAttribution=)]
    2015-10-04 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=1868946, encodeId=f004186894614, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Feb 07 11:01:00 CST 2015, time=2015-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959192, encodeId=810119591920a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Oct 04 10:01:00 CST 2015, time=2015-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752430, encodeId=cefe1e5243001, content=<a href='/topic/show?id=0ded865662' target=_blank style='color:#2F92EE;'>#Hedgehog#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8656, encryptionId=0ded865662, topicName=Hedgehog)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=544436541072, createdName=yibei, createdTime=Sat Jun 27 14:01:00 CST 2015, time=2015-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539576, encodeId=c8ad15395e67c, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Sat Nov 22 06:01:00 CST 2014, time=2014-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590258, encodeId=6d2c159025835, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Sat Nov 22 06:01:00 CST 2014, time=2014-11-22, status=1, ipAttribution=)]
    2015-06-27 yibei
  4. [GetPortalCommentsPageByObjectIdResponse(id=1868946, encodeId=f004186894614, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Feb 07 11:01:00 CST 2015, time=2015-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959192, encodeId=810119591920a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Oct 04 10:01:00 CST 2015, time=2015-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752430, encodeId=cefe1e5243001, content=<a href='/topic/show?id=0ded865662' target=_blank style='color:#2F92EE;'>#Hedgehog#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8656, encryptionId=0ded865662, topicName=Hedgehog)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=544436541072, createdName=yibei, createdTime=Sat Jun 27 14:01:00 CST 2015, time=2015-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539576, encodeId=c8ad15395e67c, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Sat Nov 22 06:01:00 CST 2014, time=2014-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590258, encodeId=6d2c159025835, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Sat Nov 22 06:01:00 CST 2014, time=2014-11-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1868946, encodeId=f004186894614, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Feb 07 11:01:00 CST 2015, time=2015-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959192, encodeId=810119591920a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Oct 04 10:01:00 CST 2015, time=2015-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752430, encodeId=cefe1e5243001, content=<a href='/topic/show?id=0ded865662' target=_blank style='color:#2F92EE;'>#Hedgehog#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8656, encryptionId=0ded865662, topicName=Hedgehog)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=544436541072, createdName=yibei, createdTime=Sat Jun 27 14:01:00 CST 2015, time=2015-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539576, encodeId=c8ad15395e67c, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Sat Nov 22 06:01:00 CST 2014, time=2014-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590258, encodeId=6d2c159025835, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Sat Nov 22 06:01:00 CST 2014, time=2014-11-22, status=1, ipAttribution=)]

相关资讯

Breast J:糖尿病和非糖尿病乳腺癌患者的肿瘤特征没有差异

Breast J:糖尿病和非糖尿病乳腺癌患者的肿瘤特征没有差异 研究背景:以往研究表明糖尿病可能会增加乳腺癌患病风险,糖尿病的生物学作用可能是增加乳腺癌风险的原因。 研究目的:本研究拟讨论患糖尿病的乳腺癌患者的临床病理特征、乳腺癌亚型是否不同于未患糖尿病的乳腺癌患者。 研究方法:从M.D.安德森肿瘤中心(MDACC)乳腺肿瘤诊疗数据库中检索1988-2005年就诊的非炎性乳腺癌患者,将其

NEJM:MEN1与乳腺癌的发生有关

N ENGL J MED:MEN1与乳腺癌的发生有关 背景:多发性内分泌瘤病是由于肿瘤抑制基因MEN1胚系突变造成的,以甲状旁腺腺瘤,十二指肠胰腺内分泌瘤,垂体腺瘤为特征,动物实验证明MEN1与乳腺癌的发生有关。 研究方法及结果:研究纳入了荷兰MEN1数据库的190名女性患者,浸润性乳腺癌的相对危险度是2.83(P<0.001),标化发病比2.14,luminal型乳腺癌的发生年龄为48.

ESSO:乳腺癌保乳头乳房切除术评价

一项来自第34届欧洲肿瘤外科大会(ESSO)的最新研究显示,低风险和晚期乳腺癌患者可实施保留乳头的乳房切除术。该手术在肿瘤学上是安全的,通过同步即时重建获得了更好的美学结果。在晚期病例中,并发症的发生率与接受乳房切除术及后续放疗的患者所报告的相似。 保留乳头的乳房切除术(NSM)被作为乳腺癌外科治疗的手术之一。它包括乳房切除术同时保留覆盖乳房和乳头乳晕复合体的皮肤。采用组织扩张器即时重建,以获得

World J Surg Oncol:纤维腺瘤来源的乳腺癌(BcaFad)的研究

World J Surg Oncol:纤维腺瘤来源的乳腺癌(BcaFad)的研究 研究背景:纤维腺瘤是女性乳腺最常见肿瘤,良性无症状的纤维腺瘤可以不用手术,定期随访,然而纤维腺瘤可以转变成癌,尽管很罕见。因此临床特征和治疗原则尚不清,了解其临床病理特征和预后以及所经过的治疗方式进行分析,有望通过分析结果得到其特征和治疗上的启示,以便于指导治疗。 研究方法:通过PUBMED搜索1986年1月

An Bras Dermatol:皮肤科医生注意,有乳腺癌患者等你来诊断。

An Bras Dermatol:皮肤科医生注意,有乳腺癌患者等你来诊断。 内脏恶性肿瘤发生皮肤转移不常见,但是乳腺癌患者常会转移到皮肤,如果这样的患者看皮肤科,那么皮肤科医生,考验你的时候到了! 这是一个来自巴西的病例报告:68岁女性因乳房间皮肤异常就诊,经检查发现皮肤呈现不规则形状红斑块,问诊后得知患者无其他疾病,未服用任何药物,无乳房及肺部恶性肿瘤家族史,近1年体检未发现宫颈及乳腺恶

EJSO:肿瘤整形手术在乳腺癌外科手术治疗的应用

来自塞尔维亚肿瘤学和放射学研究所的Djurisic等学者发表了关于肿瘤整形术在胸壁复发性叶状肿瘤治疗的应用的论文。该研究背景是肿瘤整形外科是肿瘤和整形外科的结合,遵守所有肿瘤学原则,同时为行乳腺癌手术女性患者提供满意的外观恢复。保留乳房术适用于最小的乳腺癌,完整切除肿块和周围腺体组织,同时保留乳房外观。保留乳房术与术后放疗常联合治疗。 研究视频中展示一位47岁女患者右乳腺癌保留乳腺术的技术,该患

Baidu
map
Baidu
map
Baidu
map